AbbVie Inc. (ABBV) - Equity Research Report 2026

Executive Summary

AbbVie Inc. continues to demonstrate strong market resilience. Our proprietary Equity Research Report model indicates robust fundamentals despite macroeconomic headwinds. Key catalysts include product innovation in AI and strategic cost optimization.

Valuation Methodology

We utilize a blended approach of DCF (50%) and EV/EBITDA multiples (50%). Our WACC assumption is 10.2% based on a beta of 0.88.

Risk Factors

• Regulatory scrutiny in key markets.
• Supply chain disruptions affecting gross margins.
• Intensifying competition from emerging players.